Gen House key facts
as of Oct 2026- Developer of original anti-tumor drugs designed for anti-cancer therapeutics.
- Gen House is valued at approximately $268.3M as of Oct 2026 (last reported valuation).
- It has raised $120.5M; the latest was IPO in Jan 2026.
- Notable investors include Shenzhen Capital Group, Green Pine Capital Partners, Legend Star, YuanBio Venture Capital, DPH Capital — 23 tracked in total.
- Status: In IPO Registration.
Gen House's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Gen House: the Monday email on marks, rounds and moves
Gen House funding rounds
No funding rounds for Gen House are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Gen House
23+Gen House valuation
Gen House's last reported valuation was $268 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Gen House investors
23 investors are on record for Gen House, including Shenzhen Capital Group, Green Pine Capital Partners, Legend Star and YuanBio Venture Capital. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Gen House
Developer of original anti-tumor drugs designed for anti-cancer therapeutics. The company develops new tumor immunotherapy drugs and clinical detection methods based on precision medicine, enabling patients to have better treatment through the combined drug delivery of large molecules and small molecules.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2014
- Employees
- 31
- Website
- genhousebio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.